EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...

Kyverna Therapeutics (KYTX) will present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase 1/2 studies and named patient treatments.

Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the scientific ...

Eterna Therapeutics announced promising preclinical results for its lead cell therapy, ERNA-101, aimed at treating ovarian cancer by activating the immune system. In a study conducted at MD Anderson, ...

LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic ...

Beam Therapeutics (BEAM) announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease with severe vaso-occlusive crises. The data ...

Cue Biopharma reports promising Phase 1 trial results for CUE-101 in HPV+ head and neck cancer, with significant survival rates. Cue Biopharma, Inc. has announced promising results from a Phase 1 ...

Data transferred for independent statistical analysis Top-line data expected in April 2024 NRX-101 has been awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of ...

Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...